Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,689 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06819215RecruitingPhase 1/Phase 2
VB15010 for advanced solid tumors with HRR gene mutation
This trial tests an oral medication (VB15010) in people with advanced solid tumors that have a specific DNA repair gene mutation (called HRR mutation). The goal is to see if the drug can stop or slow down cancer growth.
Jinan, ShandongAges 18–75 - NCT07408375Recruiting
Adjusting breathing machine for tumor ablation
This study tests a new way to adjust the breathing machine (ventilator) during a tumor-destroying procedure called thermal ablation. The goal is to find the safest pressure settings to protect your lungs while you are sedated.
LyonAges 18 years+ - NCT06630416RecruitingPhase 2
Pemetrexed for advanced bladder and other cancers with certain gene changes
This trial tests if a chemotherapy drug called pemetrexed works better in advanced bladder cancer or other solid tumors that have specific genetic changes (MLL4, UTX, or MTAP). It is for people who have already tried at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Birmingham, AlabamaAges Any age - NCT07755826Recruiting
Repotrectinib safety study in Japanese children with NTRK fusion tumors
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.
Minato-ku, TokyoAges 4–17 - NCT07446816RecruitingPhase 1
Study of hemay181 for advanced solid tumors
This trial tests a new drug, Hemay181, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it can shrink tumors and how safe it is.
Xinxiang, HenanAges 18–75 - NCT07231458RecruitingPhase 1
Testing a new immunotherapy with pembrolizumab for advanced solid tumors
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
BerlinAges 18 years+ - NCT00571389Recruiting
Collecting blood cells from people with cancer or COVID-19
This study collects blood cells using a special blood-draw procedure called leukapheresis (for some participants) and other samples. It aims to better understand cancer and immune-related cells, which may help researchers design or improve future treatments.
Huntersville, North CarolinaAges 5 years+ - NCT07394374RecruitingPhase 1/Phase 2
CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
BeijingAges 18 years+ - NCT06713369RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests an experimental drug called Saruparib in people with advanced solid tumors that haven't responded to standard treatments. The study will see how the drug is absorbed, distributed, and eliminated from the body.
LiverpoolAges 18 years+ - NCT01775072Recruiting
Genetic testing using stored or new cancer samples
This study collects and analyzes genetic information from tissue or blood samples to help understand cancer and related inherited (family) risk. It may involve testing results being shared with you or your care team, depending on what samples are available.
Bridgeport, ConnecticutAges Any age - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Fort Smith, ArkansasAges 18 years+ - NCT06276491RecruitingPhase 1
XmAb541 for advanced solid tumors
This phase 1 trial tests a new drug, XmAb541, for people with advanced solid tumors (ovarian, endometrial, or germ cell tumors) that have not responded to previous treatments. The trial focuses on people whose tumors have a specific protein called CLDN6 and aims to find a safe and effective dose.
Duarte, CaliforniaAges 15 years+ - NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100 - NCT07129252RecruitingPhase 1/Phase 2
A study of CRN09682 for NET and other solid tumors
This trial tests a new drug called CRN09682 for people with neuroendocrine tumors (NETs) or other solid tumors that have grown despite treatment and show a specific marker on scans. The goal is to see if the drug is safe and works against these cancers.
Phoenix, ArizonaAges 18 years+ - NCT03829254RecruitingPhase 1/Phase 2
NUC-7738 treatment for advanced solid cancers and lymphoma
This early-phase study tests how safe NUC-7738 is and how it works in people with advanced solid tumors and certain lymphomas. Some participants may also receive pembrolizumab for specific cancers, aiming to improve cancer control while carefully monitoring side effects.
CambridgeAges 18 years+ - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07189195RecruitingPhase 1
TR-002 for advanced solid tumors and pancreatic cancer
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT04308330RecruitingPhase 1
Vorinostat plus chemotherapy for advanced tumors in brain
This Phase 1 trial studies how safe and tolerable vorinostat is when combined with chemotherapy for cancers that have come back or are hard to treat, including tumors in the brain or spinal cord. It may help doctors find a better way to treat advanced solid tumors and CNS (brain/spinal cord) cancers.
Valhalla, New YorkAges 1–30 - NCT06625190RecruitingPhase 1/Phase 2
Half-matched transplant with zoledronic acid for resistant solid tumors
This trial tests a new approach using a special type of transplant (with cells from a half-matched family donor) plus a drug called zoledronic acid. It is for children and young adults with certain solid tumors that have not responded to standard treatments.
Gainesville, FloridaAges 6 months–25 years - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,689 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.